Integral Health Asset Management LLC Invests $1.74 Million in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Integral Health Asset Management LLC bought a new position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) during the fourth quarter, HoldingsChannel reports. The institutional investor bought 100,000 shares of the company’s stock, valued at approximately $1,742,000.

A number of other institutional investors have also modified their holdings of TVTX. Sterling Capital Management LLC boosted its stake in Travere Therapeutics by 859.8% in the fourth quarter. Sterling Capital Management LLC now owns 2,361 shares of the company’s stock valued at $41,000 after acquiring an additional 2,115 shares in the last quarter. R Squared Ltd acquired a new stake in Travere Therapeutics in the fourth quarter valued at approximately $53,000. Gen Wealth Partners Inc acquired a new stake in Travere Therapeutics in the fourth quarter valued at approximately $73,000. Summit Investment Advisors Inc. boosted its stake in Travere Therapeutics by 9.2% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,905 shares of the company’s stock valued at $138,000 after acquiring an additional 667 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in Travere Therapeutics in the fourth quarter valued at approximately $182,000.

Travere Therapeutics Trading Down 2.1%

Shares of NASDAQ:TVTX opened at $20.02 on Monday. Travere Therapeutics, Inc. has a 52 week low of $6.01 and a 52 week high of $25.29. The company’s 50 day moving average is $18.07 and its two-hundred day moving average is $18.83. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a market cap of $1.78 billion, a PE ratio of -4.88 and a beta of 0.88.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, May 1st. The company reported ($0.47) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.08. The firm had revenue of $81.73 million for the quarter, compared to the consensus estimate of $77.44 million. Travere Therapeutics had a negative net margin of 137.90% and a negative return on equity of 1,636.87%. The company’s revenue was up 83.3% on a year-over-year basis. During the same period last year, the firm posted ($1.76) EPS. Equities analysts predict that Travere Therapeutics, Inc. will post -1.4 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP William E. Rote sold 5,200 shares of the firm’s stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $23.53, for a total value of $122,356.00. Following the completion of the sale, the senior vice president now owns 98,519 shares in the company, valued at approximately $2,318,152.07. This trade represents a 5.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Christopher R. Cline sold 1,784 shares of the stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $21.05, for a total transaction of $37,553.20. Following the completion of the transaction, the chief financial officer now owns 93,126 shares of the company’s stock, valued at $1,960,302.30. This represents a 1.88% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 96,420 shares of company stock worth $2,302,575 in the last 90 days. Company insiders own 4.19% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on TVTX shares. Scotiabank restated an “outperform” rating on shares of Travere Therapeutics in a research note on Friday, April 11th. Guggenheim restated a “buy” rating and issued a $47.00 target price on shares of Travere Therapeutics in a research note on Monday, April 14th. Stifel Nicolaus raised their target price on shares of Travere Therapeutics from $22.00 to $23.00 and gave the company a “hold” rating in a research note on Friday, May 2nd. Evercore ISI raised their target price on shares of Travere Therapeutics from $33.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Finally, HC Wainwright lifted their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a research note on Wednesday, January 15th. Two equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $31.79.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.